---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-059749"
form_type: "8-K"
ticker: "PLX"
cik: "0001006281"
company_name: "Protalix BioTherapeutics, Inc."
filed_at: "2026-05-13T10:57:15+00:00"
generated_at: "2026-05-13T11:04:40.232979+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Protalix BioTherapeutics Reports First Quarter 2026 Financial Results and Reaffirms Guidance

## Summary
- Received $25 million milestone from Chiesi following European Commission approval of Elfabrio 2 mg/kg every-4-weeks dosing regimen.
- PRX-115 Phase 2 RELEASE study for uncontrolled gout continues; top-line results expected second half of 2027.
- Reaffirms 2026 revenue guidance of $78.0-$83.0 million including $25 million milestone; Elfabrio sales $33-$35 million, Elelyso $20-$23 million.
- Cash and equivalents $51 million as of March 31, 2026; no outstanding debt or warrants.

## SEC filing metadata
- accession: 0001104659-26-059749
- form_type: 8-K
- ticker: PLX
- cik: 0001006281
- company_name: Protalix BioTherapeutics, Inc.
- filed_at: 2026-05-13T10:57:15+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1006281/000110465926059749/0001104659-26-059749-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1006281/000110465926059749/plx-20260513x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-059749
- JSON: https://secwatch.observer/filing/0001104659-26-059749.json
- Plain text: https://secwatch.observer/filing/0001104659-26-059749.txt

## Key facts
- Earnings Releases
  Protalix BioTherapeutics, Inc. updated its the first quarter ended March 31, 2026 guidance (reaffirmed).
  - Period: the first quarter ended March 31, 2026
  - Guidance: reaffirmed
  - Result: reported results
  source text: Protalix BioTherapeutics, Inc. (the "Company") issued a press release announcing its financial results for the fiscal quarter ended March 31, 2026
  evidence_url: https://www.sec.gov/Archives/edgar/data/1006281/000110465926059749/0001104659-26-059749-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.